Opthea CKDXF

Opthea Limited is a clinical stage biopharmaceutical company engaged in the research and development of novel therapeutic products targeting Vascular Endothelial Growth Factors (VEGF) C, D and R3. The company's principal activity involves advancing drug candidates through preclinical and clinical development, with a historical focus on sozinibercept for the treatment of wet age-related macular degeneration (wet AMD). Opthea Limited operates in the biotechnology and pharmaceutical industry, specifically within the ophthalmology and VEGF inhibitor therapeutic areas.

Opthea Limited has not generated any product revenue to date, as its lead candidate, sozinibercept, remains in clinical development and has not received regulatory approval for commercial sale. The company's historical activities were centered on the development and clinical testing of sozinibercept, which was intended to be used in combination with standard-of-care anti-VEGF-A therapies for wet AMD patients. Following the failure of its Phase 3 clinical trials to meet primary endpoints in March 2025, Opthea Limited discontinued the wet AMD program and has since been streamlining operations while pursuing a strategic review to reformulate its existing VEGF-C and VEGF-D targeting compounds for potential application in other diseases.

Opthea Limited does not report any operational segments based on product lines, geography, or other business divisions. The company manages its activities as a single entity focused on the research and development of VEGF-targeted therapeutics.

Opthea Limited operates in a highly competitive biopharmaceutical landscape, particularly within the anti-VEGF therapy market for retinal diseases, where established players include Roche (with Lucentis® and Avastin®), Regeneron Pharmaceuticals (with Eylea®), and Bayer (with Eylea®). The company's competitive position has historically been rooted in its proprietary sozinibercept molecule, designed as a first-in-class VEGF-C/D trap inhibitor, which differentiated it from existing anti-VEGF-A therapies. However, following the negative outcomes of its Phase 3 trials, Opthea Limited's current competitive advantage lies in its intellectual property portfolio, including issued and pending patents covering VEGF-targeted compositions and delivery methods, as well as its expertise in VEGF-C and VEGF-D biology, which it aims to leverage in reformulating its drug candidates for new indications.

Opthea Limited does not serve any customers in the traditional sense, as it has no commercial products on the market and has not generated revenue from product sales. The company's historical activities involved interactions with clinical trial sites, patients enrolled in its studies, and third-party contractors for manufacturing and trial execution. Following the discontinuation of its wet AMD program, Opthea Limited has no active customer base related to product distribution or commercialization efforts.